Galactose-deficient IgA1 (Gd-IgA1) attracts a lot of attention as a critical effector molecule in the pathogenesis and progression of IgA nephropathy (IgAN) in many recent studies.
It is suggested that several O-link glycans modified regions exist in the heavy chain hinge region of human IgA1 molecules and Gd-IgA1 circulates in blood stream of the patients with the pathological condition of IgAN.
The measuring system using snail (helix aspersa; HAA) lectin has been used in numerous past studies and revealed that serum levels of Gd-IgA1 in patients with IgAN is significantly elevated compared with the level of healthy subjects or patients with renal diseases other than IgAN. Thus, the importance and purpose of measuring serum Gd-IgA1 levels has been gradually recognized.
However, since the measuring system using HAA lectin is not suitable for measuring multiple and massive samples in large scale studies due to its instability of glycan-recognizing activity, development of alternative measuring system that can quantitatively measure human Gd-IgA1 in serum with stable and reliable data has been considered an essential and urgent matter. The IBL Galactose-deficient IgA1 (Gd-IgA1) ELISA kit uses a monoclonal antibody that specifically recognizes galactose-deficient hinge sequences of human Gd-IgA1. It is a lectin non-dependent measuring system that can measure Gd-IgA1 in human serum and EDTA-plasma and is also suitable for large scale studies because of its stability.